In This Section

DMD Virtual Special Sections

Virtual Special Section (VSS) on “Drug metabolism by the gut microbiota”

VSS Editor: Young Jeong, Virtual Special Section Editor
Submission Deadline: December 31, 2024

DMD invites original research articles and mini-reviews on topics related to drug metabolism by the gut microbiota. These include, but are not limited to, studies on the identification/characterization of novel biotransformation reactions or drug metabolism by microbes and their impact on drug therapy; absorption/distribution/metabolism/excretion studies of drugs that undergo gut microbial metabolism. Mini-reviews on current research advances and perspectives on the relevant research are also encouraged.

Drug metabolism by the gut microbiota

  1. Gut Microbiome Integration in Drug Discovery and Development of Small Molecules
    Patrick Jimonet, Céline Druart, Stephanie Blanquet-Diot, Lilia Boucinha, stephanie Kourula, Françoise Le Vacon, Sylvie Maubant, Sylvie Rabot, Tom Van de Wiele, Frank Schuren, Vincent Thomas, Bernard Walther and Michael Zimmermann
  2. Discovery of Unprecedented Human Stercobilin Conjugates
    Sungjoon Cho, Lionel Cheruzel, Jingwei Cai, Stephen K. Wrigley, Renia T. Gemmell, Tetsuo Kokubun, Jonathan C. P. Steele, Laurent Salphati, Donglu Zhang and S. Cyrus Khojasteh

 

Virtual Special Section (VSS) on “Endogenous biomarkers of drug-metabolizing enzymes and transporters”

VSS Editor: Yurong Lai
Submission Deadline: March 31, 2025

DMD invites original research articles and mini-reviews on topics related to the endogenous biomarkers of drug-metabolizing enzymes or transporters. These include, but not limited to, studies on the identification, translation and verification of endogenous biomarkers (e.g., metabolites, genetic polymorphisms or organ impairment) to assess drug disposition or drug-drug interactions. We also welcome mini-reviews on current perspectives on relevant topics. Manuscripts will be reviewed as they are submitted. Accepted papers will be published in a regular DMD issue and archived here in the Special collection as a Virtual Special Issue.

Endogenous biomarkers of drug-metabolizing enzymes and transporters

  1. Effect of Cimetidine on Metformin Pharmacokinetics and Endogenous Metabolite Levels in Rats
    Anoud Sameer Ailabouni, Vijaya Saradhi Mettu, Aarzoo Thakur, Dilip Kumar Singh and Bhagwat Prasad
  2. Assessing Pleiotropic Effects of a Mixed-Mode Perpetrator Drug, Rifampicin, by Multiple Endogenous Biomarkers in Dogs
    Renmeng Liu, Bin Ma, Marilyn M. Mok, Bernard P. Murray, Raju Subramanian and Yurong Lai

 

Virtual Special Section (VSS) on “Novel Animal Models”

VSS Editor: Hiroshi Yamazaki
Submission Deadline: April 30, 2025

DMD invites original research, mini-reviews and perspectives on topics related to novel animal models for predicting drug metabolism and toxicity in human patients and animal species under veterinary care for a new Virtual Special Section. Accepted papers will be published in a regular DMD issue and archived here in the Special collection as a Virtual Special Issue.

Novel Animal Models

  1. Novel Cytochrome P450 2C119 Enzymes in Cynomolgus and Rhesus Macaques Metabolize Progesterone, Diclofenac, and Omeprazole
    Yasuhiro Uno, Norie Murayama and Hiroshi Yamazaki
  2. Novel Tree Shrew Cytochrome P450 2Ds (CYP2D8a and CYP2D8b) Are Functional Drug-Metabolizing Enzymes that Metabolize Bufuralol and Dextromethorphan
    Genki Ushirozako, Norie Murayama, Kyoko Tsukiyama-Kohara, Hiroshi Yamazaki and Yasuhiro Uno
  3. Pharmacokinetic Models Scaled Up from Humanized Liver Mouse Data Can Account for Drug Monitoring Results of Atomoxetine and Its 4-Hydroxylated and N-Demethylated Metabolites in Pediatric Patients Genotyped for Cytochrome P450 2D6
    Makiko Shimizu, Shotaro Uehara, Katsuhiro Ohyama, Haruka Nishimura, Yoichi Tanaka, Yoshiro Saito, Hiroshi Suemizu, Sayaka Yoshida and Hiroshi Yamazaki
  4. Pharmacokinetic Effects of Different Models of Nonalcoholic Fatty Liver Disease in Transgenic Humanized OATP1B Mice
    Baron J Bechtold, Katherine D Lynch, Victoria O Oyanna, M Ridge Call, Laura A White, Tyler N Graf, Nicholas H. Oberlies and John D. Clarke
  5. Investigation of functional cytochrome P450 4A enzymes in liver and kidney of pigs, cats, tree shrews, and dogs in comparison with the metabolic capacity of human P450 4A11
    Yasuhiro Uno, Kyoko Tsukiyama-Kohara, Mayumi Ishizuka, Hazuki Mizukawa, Norie Murayama and Hiroshi Yamazaki

Virtual Special Section (VSS) on “Sex and hormonal influences on drug metabolism and disposition, and related studies”

VSS Editor: David Riddick
Submission Deadline: April 30, 2025

DMD invites original research articles and mini-reviews on topics related to sex differences in or hormonal regulation of any aspects of drug metabolism, drug transport or drug disposition. Mechanistic studies of the metabolism, transport or disposition of endogenous hormones or exogenous endocrine-disrupting chemicals are also welcomed. Consideration will be given to studies including, but not limited to, in vitro systems, animal models and clinical investigations.

Sex and hormonal influences on drug metabolism and disposition,
and related studies

  1. Activation of the YY1-UGT2B7 axis promotes mammary estrogen homeostasis dysregulation and exacerbates breast tumor metastasis
    Jiahao Xu, Ying Zhou, Shiqing He, Yinghao Wang, Jiachen Ma, Changwen Li, Zhao Liu and Xueyan Zhou
  2. HCV Antiviral Drugs Have the Potential to Adversely Perturb the Fetal-Maternal Communication Axis through Inhibition of CYP3A7 DHEA-S Oxidation
    Hannah M. Work, John C. Hackett and Jed N. Lampe

Virtual Special Section (VSS) on “Protein degraders ADMET”

VSS Editor: Scott Obach
Submission Deadline: April 30, 2025

DMD is inviting original research articles and reviews on the topic of protein degraders (a.k.a. PROTACS). Over the past several years, protein degrader molecules have offered those involved in designing and developing new drugs a novel modality and mechanism for engaging pharmacological targets. However, the complexity of their chemical structures has also posed new challenges to drug disposition scientists engaged in characterizing their ADME properties. Furthermore, their mode of action has generated new challenges to researchers engaged in understanding pharmacokinetic-pharmacodynamic (PK/PD) relationships for these novel molecules. We invite papers describing the overall disposition of protein degrader molecules in mammalian systems, their metabolism, how they can be dosed and delivered, how technical challenges working with these molecules in the lab can be overcome, as well as modeling their PK/PD, and PB/PK relationships, among other topics.

Protein degraders ADMET

  1. Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders
    Laurie P. Volak, Heide Marika Duevel, Sara Humphreys, David Nettleton, Colin Phipps, Andy Pike, Caroline Rynn, Paul Scott-Stevens, Donglu Zhang and Michael Zientek

Virtual Special Section (VSS) on “AI-based prediction of drug disposition and toxicity”

VSS Editor: Sean Ekins
Submission Deadline: July 31, 2025
DMD is inviting original research articles and minireviews on the topic of AI-based prediction of drug disposition and toxicity. AI has been constantly in the news in recent years so there is considerable excitement and hype around what this technology can do in many different areas. Drug discovery is not immune from this. Even though computational approaches have been applied in many areas from toxicity, metabolism and drug-drug interaction prediction for several decades, the recent availability of bigger datasets (big data), more powerful computational power (cloud computing, GPUs) and algorithms (deep learning, transformers - large language models) provides a foundation for broader impact in the field. We would like to explore the potential of AI for ADME and toxicity prediction to separate the hype from the reality and now invite your article submissions.

Virtual Special Section (VSS) on “Bench-to-Bedside: Drug Metabolizing Enzymes and Transporters (DMETs) in Drug Disposition in Specific Population”

Guest Editor: Paresh Chothe
Submission Deadline: April 30, 2025
DMD is inviting original research articles and reviews on the topic of “Bench-to-Bedside: Drug Metabolizing Enzymes and Transporters (DMETs) in Drug Disposition in Specific Population.” The advancements in in vitro methodologies, proteomics, IVIVE methods, and PBPK modeling have revolutionized our ability to quantitatively predict the role of DMETs in ADME and DDIs. However, the paucity of data regarding alterations in DMETs activity in specific populations such as pregnant individuals, pediatrics, disease states has restricted our ability to realize the full potential of these recent advancements. A special supplementary issue focusing on in silico, in vitro, and in vivo approaches to characterize alteration in DMET activity and predict drug disposition in specific populations could provide valuable insights for researchers in the field of drug metabolism and disposition.

Bench-to-Bedside: Drug Metabolizing Enzymes and Transporters (DMETs) in Drug Disposition in Specific Population

  1. Comparison of the CYP3A selective inhibitors CYP3cide, clobetasol, and azamulin for their potential to distinguish CYP3A7 activity in the presence of CYP3A4/5
    Hannah M. Work, Sylvie E. Kandel and Jed N. Lampe
  2. Quantitative Proteomics for Translational Pharmacology and Precision Medicine: State of The Art and Future Outlook
    Bhagwat Prasad, Zubida M. Al-Majdoub, Christine Wegler, Amin Rostami-Hodjegan and Brahim Achour
 

Manuscripts will be reviewed as they are submitted. Accepted papers will be published in a regular DMD issue and archived here in the special collection as a Virtual Special Section Issue. Virtual Special Section content will be freely available for six months after acceptance.

For questions about submitting a manuscript to this Virtual Special Section, contact DMD@aspet.org.

Job Postings